DEFINING THE ART OF CANCER TREATMENT

NEW HOPE FOR POOR PROGNOSIS CANCER PATIENTS

THERAPEUTIC APPROACH

Blue Wave Therapeutics is developing an innovative biopolymer-radionuclide targeted platform technology, to target residual cancer cells of patients with low survival rates. The deadliest of brain cancers, glioblastoma, is Blue Wave Therapeutics’ first targeted indication. 

INNOVATIVE, EFFECTIVE AND SAFE

Radionuclide therapy has shown excellent results as a targeted treatment for various cancer types, with a benign safety profile.

LOCALLY ADMINISTERED AND TARGETED

The radio-charged polymer is locally administered with a one-time, easy-to-use injection in situ. The biopolymer specifically binds to the tumor cells.

SUITABLE FOR MULTIPLE CANCERS

Multiple cancers with a high medical need, i.e. pancreatic, breast, cervical, colon and lung cancer, can  be targeted through our proprietary platform technology.

CONVENIENCE FOR PATIENTS​

In glioblastoma the use of this technology is intended as adjuvant therapy, i.e. given after surgery with no need of subsequent removal.

THE NEXT GENERATION ADJUVANT THERAPY FOR GLIOBLASTOMA

Glioblastoma is a devastating disease. It is the most aggressive primary brain tumor with serious unmet medical need, as it metastasizes quickly in the brain and can double the size in 10 days. Despite available therapies, the prognosis is extremely poor. The majority of patients do not survive for more than two years following diagnosis, and the median survival is generally less than a year. The average 5-year survival rate is less than 3%. 

The standard treatment is surgery followed by external beam radiation therapy and chemotherapy. However, healthy brain tissue is also receiving a considerable dose when treated, thus limiting the therapeutic efficacy of these treatments.

THE NEXT GENERATION ADJUVANT THERAPY FOR GLIOBLASTOMA

Patient with glioblastoma
After surgery, the radio-charged biopolymer is injected into the surgical cavity
Residual tumor cells are irradiated continuously, until radionuclide decays
 
Upon biopolymer degradation and radiation decays, the brain tissue slowly fills the cavity

OUR GOAL IS TO GIVE PATIENTS A SECOND CHANCE

ABOUT US

MANAGEMENT TEAM CONSISTING OF EXPERIENCED BIOTECH LEADERS AND HIGHLY QUALIFIED SCIENTISTS

MARCO RENOLDI, MD

Chief Executive Officer

MICHAEL DORNISH, PHD

Chief Scientific Officer
 

LUCA SERENI

Chief Operating Officer
 

JOSTEIN DAHLE, PHD

Chief Technical Officer
  

LUIGI COSTA

Luigi has been Board member at Blue Waves Therapeutics  since April 2021 through February 24, 2024.
Blue Wave Therapeutics GmbH was established in Switzerland in 2021. Its R&D
subsidiary Blue Wave Therapeutics AS, is located in Norway..

NEWS

Blue Wave Therapeutics has just been awarded a non-dilutive grant of NOK 16 million by the Norwegian Research Council, marking a significant milestone in our journey towards revolutionizing cancer therapeutics. Our proprietary integrin-targeting, alpha-particle emitting, biopolymer nanospheres aim to prolong survival and quality of life of glioblastoma patients via a single administration following surgery.

This generous grant is not just a financial boost; it’s a resounding endorsement of the scientific foundation that underpins Blue Wave Therapeutics’ groundbreaking technology platform. This grant is also a testament to the potential of our therapeutic approach to make a lasting impact on the lives of those affected by cancer, and a reflection of the unwavering commitment and  capabilities of our team.

As we celebrate this milestone, we are energized and more determined than ever to translate this support into tangible advancements for cancer patients.

Thank you to the Norwegian Research Council for recognizing our potential, and to our incredible team for turning that potential into reality. Together, we are shaping the future of cancer care.

GET IN TOUCH WITH US

First
Last

CONTACTS

info@bluewavetherapeutics.com

HEADQUARTER

Breitenstrasse 85c
8832 Wilen b. Wollerau
SWITZERLAND – CH

Privacy Policy